This is in line with our findings, where the mutation’s identification suggests the potential for EGFR TKI therapy as a first-line treatment, as these therapies can block the constitutive activation of EGFR signaling, leading to reduced tumor proliferation and enhanced patient survival. Here, EGFR is linked to neoplasm.